Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

At Drug Pricing Hearing, Innovator Companies Mainly Escape Congressional Wrath

This article was originally published in The Pink Sheet Daily

Executive Summary

Members of House Oversight Committee accuse Turing and Valeant of 'trashing' mainstream innovator companies with their drug pricing practices.

Advertisement

Related Content

EpiPen Price Hearing: House Plays Bootleg Tape Of Shkreli Event
Mylan's EpiPen Nightmare Not Over Yet, But Will Congress Just Write?
Congress Already Impacting Industry Drug Pricing Abuses, Valeant Says
Legislators And Bond Holders Knocking At Valeant’s Door
Valeant Settles One Legal Headache But Still Faces Congressional, DOJ Probes
Industry Assesses Threat From Drug-Pricing Debate
The Super Bowl of Mismanaging Congressional Investigations: Shkreli Vs. Valeant
Eye Of The Pricing Storm: FDA's Woodcock Withstands Gale-Force Rhetoric
PhRMA Takes Aim At Valeant In Defense Of Drug Pricing By ‘Innovative’ Firms

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079172

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel